SeqLL, Inc. (SQL): Price and Financial Metrics
GET POWR RATINGS... FREE!
SQL Stock Price Chart Interactive Chart >
SQL Price/Volume Stats
Current price | $0.79 | 52-week high | $5.80 |
Prev. close | $0.79 | 52-week low | $0.65 |
Day low | $0.75 | Volume | 6,400 |
Day high | $0.79 | Avg. volume | 77,611 |
50-day MA | $1.14 | Dividend yield | N/A |
200-day MA | $0.00 | Market Cap | 9.36M |
SeqLL, Inc. (SQL) Company Bio
SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It designs, develops, and manufactures genetic analysis technologies; and offers true single molecule sequencing (tSMS) platform that assists researchers to develop research, diagnostics, and therapeutics applications. The company also provides RNA sequencing services and instruments, which include Direct RNA Sequencing, a genetic testing and mapping service that captures polyadenylated RNA directly without conversion to cDNA; tSMS formalin fixed paraffin embedded (FFPE) service to analyze damaged or fragmented nucleic acids from formalin fixed paraffin embedded samples and other sources; micro RNA sequencing; and custom sequencing, and mapping and testing services, as well as gene expression studies, FFPE RNA Sequencing, biomarker discovery, fusion detection, rare mutation detection, transcriptome profiling, and cap analysis gene expression services. In addition, it offers DNA sequencing services and instruments, such as shotgun DNA sequencing, direct capture sequencing, cell free DNA sequencing, FFPE DNA sequencing, ancient DNA sequencing, and targeted sequencing, as well as microbiome studies, biomarker discovery, and tumor profiling services. Further, the company provides bioinformatics services comprising data processing, biomarkers research, pathway analysis, and gene expression analysis services, as well as undertakes various custom projects. It has a collaboration agreement with Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. The company serves academic and government institutions, hospitals and medical centers, pharmaceutical and biotechnology companies, and non-profit research organizations. SeqLL Inc. was founded in 2013 and is based in Woburn, Massachusetts.
Latest SQL News From Around the Web
Below are the latest news stories about SeqLL Inc that investors may wish to consider to help them evaluate SQL as an investment opportunity.
SeqLL Inc. Announces Closing of Underwriters’ Option to Purchase Additional Shares of Common Stock in Connection with its Initial Public OfferingWOBURN, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ:SQL; SQLLW), a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields, today announced the closing of the sale of an additional 189,000 shares of common stock at the initial public offering price of $4.24 per share, pursuant to the partial exercise of the underwriters’ |
SeqLL Announces Publication of a New Blood-Based RNA Sequencing Method to Detect Coronary Artery DiseaseGW-Led Research uses SeqLL’s tSMS® platform to identify novel signature for detection of coronary artery diseaseWOBURN, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields, today announced the peer-reviewed publication of a new blood-based RNA Sequencing method to d |
SeqLL Announces Publication of a New Single-Cell Epitranscriptomic Method Powered by SeqLL’s tSMS® PlatformMethod developed by leading researchers at the Bernstein Laboratory and SeqLL Inc. Funding for the research and method development provided by the National Institutes of Health (NIH) WOBURN, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields, today announced the pe |
7 Biotech Stocks to Buy That Have Millionaire-Maker PotentialWhile the term “technology” often brings to mind the broader digitalization movement, tech actually has the most potential in healthcare. Thanks to groundbreaking innovations, we now know much more about the human body and how various diseases work. So, in time, we will likely transition from preventative measures to more remedial solutions. That bolsters the big-picture argument for biotech stocks. Of course, when the pandemic first struck, everything changed. Due to various mitigation protocol |
SeqLL Inc. Announces Closing of Upsized $13 Million Initial Public OfferingWOBURN, MA, Aug. 31, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ:SQL; SQLLW), a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields, today announced the closing of its previously announced initial public offering of 3,060,000 shares of its common stock and accompanying warrants to purchase up to 3,060,000 shares of common stock. Each |
SQL Price Returns
1-mo | -31.90% |
3-mo | -41.04% |
6-mo | -72.66% |
1-year | N/A |
3-year | N/A |
5-year | N/A |
YTD | -57.75% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
2018 | N/A |
2017 | N/A |
Loading social stream, please wait...